These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11340368)

  • 21. Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.
    Gianotti LR; Künig G; Faber PL; Lehmann D; Pascual-Marqui RD; Kochi K; Schreiter-Gasser U
    Psychopharmacology (Berl); 2008 Jun; 198(3):323-32. PubMed ID: 18446328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivastigmine. A review of its use in Alzheimer's disease.
    Spencer CM; Noble S
    Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Jann MW
    Pharmacotherapy; 2000 Jan; 20(1):1-12. PubMed ID: 10641971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivastigmine in the treatment of Alzheimer's disease.
    Deleu D
    Eur Neurol; 2001; 46(2):110. PubMed ID: 11528167
    [No Abstract]   [Full Text] [Related]  

  • 26. Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
    Desai A; Grossberg G
    Expert Opin Pharmacother; 2001 Apr; 2(4):653-66. PubMed ID: 11336614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
    Gasser US; Gasser T
    MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165
    [No Abstract]   [Full Text] [Related]  

  • 28. [New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].
    Dtsch Med Wochenschr; 1998 Nov; 123(48 Suppl):1-4. PubMed ID: 9861229
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

  • 30. [Rivastigmine: a review of its clinical effectiveness].
    Spiegel R
    Rev Neurol; 2002 Nov 1-15; 35(9):859-69. PubMed ID: 12436385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivastigmine: a review.
    Sim A
    Hosp Med; 1999 Oct; 60(10):731-5. PubMed ID: 10656066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electroconvulsive therapy in a patient receiving rivastigmine.
    Zink M; Sartorius A; Lederbogen F; Henn FA
    J ECT; 2002 Sep; 18(3):162-4. PubMed ID: 12394536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
    Mustazza C; Borioni A; Del Giudice MR; Gatta F; Ferretti R; Meneguz A; Volpe MT; Lorenzini P
    Eur J Med Chem; 2002 Feb; 37(2):91-109. PubMed ID: 11858843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
    Chen Y; Shohami E; Constantini S; Weinstock M
    J Neurotrauma; 1998 Apr; 15(4):231-7. PubMed ID: 9555969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivastigmine in subcortical vascular dementia: an open 22-month study.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rivastigmine in Alzheimer disease: efficacy over two years.
    Grossberg G; Irwin P; Satlin A; Mesenbrink P; Spiegel R
    Am J Geriatr Psychiatry; 2004; 12(4):420-31. PubMed ID: 15249280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythematous maculopapular eruption due to rivastigmine therapy.
    Monastero R; Lopez G; Mannino M; Camarda R
    Am J Med; 2001 Nov; 111(7):583-4. PubMed ID: 11705442
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA approves new cholinesterase inhibitor for Alzheimer's disease.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1026, 1028. PubMed ID: 10876742
    [No Abstract]   [Full Text] [Related]  

  • 39. [Alzheimer disease: efficacy and tolerance of rivastagmine].
    Hébert M
    Presse Med; 1999 Oct; 28(32):1757-8. PubMed ID: 10566280
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.